Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2023
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2023
OSAKA, Japan, June 26, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2024 (the "Annual Report") with the U.S. Securities and Exchange Commission (the "SEC") on June 26, 2024. The Annual Report can be accessed on Takeda's website at: https://www.takeda.com/investors/sec-filings-and-security-reports/.
2024年6月26日，日本大阪——武田制药（SKYLINE（TAK-935-3001）是一项多中心、随机、双盲的3期研究，评估了Soticlestat（TAK-935）与标准板的联合用药与安慰剂和标准板的联合用药在难治性德拉维特综合征（DS）患者中的疗效。）宣布已向美国证券交易所（"SEC"）提交了截至2024年3月31日的财政年度的20-F表格的年度报告（"年度报告"），日期为2024年6月26日。年度报告可以在武田公司的网站上访问：https://www.takeda.com/investors/sec-filings-and-security-reports/.
In addition, Takeda will also provide a hard copy of the Annual Report, which includes its most recent complete audited financial statements free of charge to any shareholder upon request. Please contact Takeda Investor Relations by e-mail at takeda.ir.contact@takeda.com.
此外，武田公司将免费提供最新完整审计财务报表的硬拷贝年度报告给任何股东。请通过电子邮件联系武田投资者关系：takeda.ir.contact@takeda.com.
About Takeda
关于武田公司 武田公司致力于为人们创造更健康的未来，为世界带来更光明的前景。我们的核心治疗和业务领域包括消化道和炎症、罕见病、血浆衍生治疗、肿瘤、神经科学和疫苗，旨在发现和推出改变生命的治疗方案。与我们的合作伙伴一道，通过我们具有活力和多样化的管道，我们的目标是改善患者的体验，推进新的治疗选择。作为总部位于日本的基于价值观和以研发为驱动的生物医药公司的领导者，我们的指导方针是致力于患者、我们的员工和地球的保护。我们在大约80个国家和地区的员工是由我们的使命和超过两个世纪以来定义我们的价值观所驱动的。有关更多信息，请访问www.takeda.com。
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Takeda专注于为人们创造更好的健康和更美好的未来。我们的目标是在我们的核心治疗和业务领域，包括肠胃炎症、罕见疾病、血浆衍生疗法、肿瘤学、神经科学和疫苗学中发现和提供变革人生的治疗方案。与我们的伙伴一起，我们的目标是通过我们充满活力和多样化的流水线，改善患者的体验并推动新的治疗选择的先锋。作为日本总部设在日本的一家领先的以价值为导向的研发型生物制药公司，我们是由我们对患者、人民和地球的承诺所引导的。我们在大约80个国家和地区的员工以我们的宗旨为主导，并以已经定义我们两个多世纪的价值为根基。有关更多信息，请访问www.takeda.com.